Literatur
-
1
Gasse G, Hense H W, Stiebler J. et al .
Assessing hypertension management in the
community.
J Human Hypertens.
2001;
15
27-36
-
2
Guidelines Subcommittee .
1999
World Health Organization-International Society of Hypertension
guidelines for the management of hypertension.
J Hypertens.
1999;
17
151-183
-
3
Hansson L. et al .
Excess morbidity and cost of failure to
achieve targets for blood pressure control in Europe.
Blood
Pressure.
2002;
11
35-45
-
4
Kolloch R, Offers E.
Vasopeptidase-Inhibition.
Dtsch
Med Wochenschr.
2001;
126
1342-1347
-
5
Kreutz R.
Pharmakogenomik
und Pharmakogenetik bei der arteriellen Hypertonie.
Dtsch
Med Wochenschr.
2000;
125
1403-1410
-
6
Unger T, Rangoonwala B, Rosenthal J.
ACE_Hemmer
oder AT1-Antagonist: Gibt es eine Differenzialtherapie?.
MMW
Fortschr Med.
2002;
144
36-38
-
7
Zanchetti A, Hansson L, Ménard J. et al .
Risk assessment and treatment benefit in
intensely treated hypertensive patients of the Hypertension Optimal
Treatment (HOT) study.
J Hypertens.
2001;
19
819-825
Prof. Dr. med. Thomas Unger
Institut für Pharmakologie und Toxikologie, Klinikum
Charité der Humboldt-Universität zu Berlin
Dorotheenstraße
94
10117 Berlin
Phone: 030/45052
5001
Fax: 030/45052 5901
Email: thomas.unger@charite.de
